Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 8/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 2/20 | 0.33 |
| ▸ | ARG2 | P78540 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9543424 | 1.00 | FDPS (0.36) | FDPSCTSKCTSSDGAT1ARG1 | |
| Ammonia Solution, Strong SCHEMBL28292145 | 0.98 | FDPS (0.35) | FDPSCTSKCTSSDGAT1ARG1 | |
| Hydrochloric Acid SCHEMBL28182381 | 0.98 | FDPS (0.35) | FDPSCTSKCTSSDGAT1ARG1 | |
| SCHEMBL29762781 | 0.93 | SMPD1 (0.40) | FDPSSMPD1MEN1ALDH1A1KMT2A | |
| SCHEMBL8001832 | 0.93 | SMPD1 (0.40) | FDPSSMPD1MEN1ALDH1A1KMT2A | |
| SCHEMBL17768312 | 0.93 | SMPD1 (0.40) | FDPSSMPD1MEN1ALDH1A1KMT2A | |
| SCHEMBL4825036 | 0.93 | SMPD1 (0.40) | FDPSSMPD1MEN1ALDH1A1KMT2A | |
| SCHEMBL6372947 | 0.89 | DGAT1 (0.36) | FDPSCTSKCTSSDGAT1ARG1 | |
| Ammonia Solution, Strong SCHEMBL27708715 | 0.87 | DGAT1 (0.35) | FDPSCTSKCTSSDGAT1ARG1 | |
| SCHEMBL9016090 | 0.86 | ODC1 (0.42) | DGAT1ARG1ARG2GGT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109355310-A | ROS (reactive oxygen species) -responsive gene delivery vector as well as preparation method and application thereof | 南京工业大学 | 2019-02-19 | — | — | CN | claimed |
| CN-107233581-A | One kind can carry out the imaging of MR fluorescent dual module states lymph, degradable small particle nano-micelle and its preparation method and application | 中山大学 | 2017-10-10 | — | — | CN | claimed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250114448-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE (ES) | 2025-04-10 | — | — | US | disclosed |
| CN-119661630-A | Thixotropic small molecule gel, preparation method and application thereof | 西安交通大学 | 2025-03-21 | — | — | CN | disclosed |
| EP-4466278-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) | 2024-11-27 | — | — | EP | disclosed |
| CN-118930469-A | Compound for delivering small nucleic acid to brain cells and application thereof | 圣诺生物医药技术(苏州)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114702506-B | 11-carbonyl-20-ethoxy source oridonin and 14-OH esterified serial derivatives and application thereof | 郑州大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-4219518-A2 | BIOCONJUGATES OF HETEROCYCLIC COMPOUNDS | Taizhou Huifeng Hetai Biotechnology Co. Ltd (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023139145-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2023-07-27 | — | — | WO | disclosed |
| US-11464864-B2 | Drug-bound compound and use thereof | SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) | 2022-10-11 | — | — | US | disclosed |
| CN-1080720-C | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-6342225-B1 | FOR THERAPY OF DIABETES MELLITUS | DEUTSHCES WOLLFORSCHUNGSINSTITUT (DE) | 2002-01-29 | — | — | US | disclosed |
| US-6063761-A | ANTIDIABETIC AGENTS | KINGS COLLEGE LONDON (GB) | 2000-05-16 | — | — | US | disclosed |
| CN-1224718-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| US-5854208-A | Hepatoselective pharmaceutical actives | DEUTSCHES WOLLFORSCHUNGSINSTITUT (DE) | 1998-12-29 | — | — | US | disclosed |
| EP-0725648-A1 | HEPATOSELECTIVE PHARMACEUTICAL ACTIVES | THE UNITED MEDICAL AND DENTAL SCHOOLS OF GUY'S AND ST. THOMAS'S HOSPITALS (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995005187-A1 | HEPATOSELECTIVE PHARMACEUTICAL ACTIVES | UNITED MEDICAL & DENTAL SCHOOLS OF GUY'S AND ST THOMAS' HOSPITALS (GB) | 1995-02-23 | — | — | WO | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | FDPS 3299/4885CTSK 3500/4885CTSS 4169/4885 |
| US-11464864-B2 | Drug-bound compound and use thereof | SLC2A9, ABCB1, SLC5A7 | FDPS 1640/4885CTSK 4042/4885CTSS 4141/4885 |
| US-20250114448-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | STT3A, STT3B, DDOST | FDPS 1087/4885CTSK 3989/4885CTSS 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.